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Using the differentiation antigen Pmel17/gp100 to
genetically immunize C57BL/6 mice (H-2b), we and
others noticed that only mice that had received the
human homolog but not animals injected with the
murine counterpart were protected against the growth
of syngeneic B16 melanoma cells. The goal of this
study was to determine whether the state of non-
responsiveness to the autoantigen Pmel17/gp100 can
be broken by immunization with a plasmid DNA
construct encoding the autologous form of the mole-
cule. A construct containing the murine form of
Pmel17 was administered intradermally to DBA/2
mice (H-2d), which were then investigated for the pre-
sence of Pmel17/gp100-speci®c immunity. We show
that administration of plasmid DNA coding for the
autologous melanoma-associated antigen Pmel17/
gp100 protects DBA/2 mice against the growth of
Pmel17-positive M3 melanoma cells but not against
Pmel17-negative M3 melanoma cells or unrelated
P815 mastocytoma cells. Cell depletion experiments
demonstrated that this protective effect is mediated
by T lymphocytes. The notion that Pmel17/gp100
represents the biologically relevant target in this
system was supported by the observations (i) that
recipients of Pmel17/gp100 DNA mount an antigen-
speci®c cytotoxic T lymphocyte response and (ii) that
M3 tumors growing in mice immunized with autolo-
gous Pmel17/gp100 had lost expression of this mela-
noma-associated antigen whereas M3 melanomas
appearing in control-vector-treated animals were still
Pmel17/gp100-positive. These results indicate that
intracutaneous genetic immunization with autologous
melanoma-associated antigen Pmel17/gp100 encod-
ing plasmid DNA can lead to protection against mela-
noma cells as a result of the induction of a melanoma-
associated antigen-speci®c and protective T-cell-
mediated immune response. Key words: CTL/gene ther-
apy/in vivo animal models/rodent/tumor immunity. J Invest
Dermatol 115:1082±1087, 2000
W
ith the recent identi®cation of tumor-asso-
ciated antigens recognized by cytotoxic T
lymphocytes (CTL) and the cloning of their
respective gene sequences the combat against
cancer by strategies aimed at enhancing anti-
gen-speci®c cell-mediated immune responses became a realistic
possibility. These melanoma-associated antigens (MAA)3 include the
cancer/testis antigens (e.g., MAGE, BAGE, GAGE families) as well as
nonmutated melanocytic differentiation antigens such as Pmel17/
gp100, tyrosinase, MelanA/MART-1, and tyrosinase-related pro-
teins (TRP) 1 and 2. These antigens are able to sensitize melanoma
cells for recognition in vitro by CTL derived from melanoma patients,
and can serve as target structures during regression of melanoma
metastases in vivo (Rosenberg, 1997).
One of the ultimate goals of tumor antigen identi®cation is to
analyze their use as candidate tumor rejection antigens in
recombinant vaccine strategies. The ef®cacy of the latter is
determined by many factors including the vector system chosen,
the route of application of the immunizing agent, the immuniz-
ation intervals, the use of adjuvant, and the nature of the antigen
itself (Cohen et al, 1998). As it is impossible to compare the
in¯uence or contribution of all these factors on initiation and
maintenance of the antitumor immune responses in patients, the
availability of corresponding experimental animal models may
provide the unique opportunity to delineate the general principles
of different vaccination protocols in a preclinical setting. The
situation is complicated by the fact that, in contrast to their human
counterpart, the majority of murine tumor rejection antigens are
uniquely expressed by individual tumors (reviewed by Jaffee and
Pardoll, 1996). As a consequence, vaccination studies in experi-
mental models have been performed using arti®cial, often highly
immunogenic, surrogate antigens such as ovalbumin, viral proteins,
or xenogeneic forms of tumor antigens.
With the recent cloning of mouse homologs to human
melanoma differentiation antigens it became possible to test these
antigens for their suggested in vivo role as tumor rejection antigens
(Bloom et al, 1997; Zhai et al, 1997; Schreurs et al, 1998; Weber
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et al, 1998; Overwijk et al, 1999). This is of great importance
because of the central and peripheral immunologic tolerance that
may exist to self-antigens (Guerder and Matzinger, 1992; Akkaraju
et al, 1997) and has to be broken for an effective antitumor immune
response to occur. Recently, we and others demonstrated that
different immunization strategies against the MAA Pmel17/gp100
can lead to a protective in vivo antitumor immune response in the
experimental B16/C57BL/6 (H-2b) mouse melanoma model (Zhai
et al, 1996; MoÈlling et al, 1997; Schreurs et al, 1998; Kaplan et al,
1999). In this animal model, however, protective immune
responses were elicited either exclusively (Zhai et al, 1996;
MoÈlling et al, 1997; Schreurs et al, 1998) or predominantly
(Kaplan et al, 1999) by xenoimmunization with human Pmel17/
gp100, probably because of the fortuitous existence of a highly avid
human peptide homolog that, when presented in the context of
H-2b, would initiate a crossreactive T cell response towards murine
Pmel17/gp100 (Overwijk et al, 1998). As nonresponsiveness to
immunization with autologous differentiation antigens would have
important clinical implications, we wondered whether the situation
in C57BL/6 mice is a strain-speci®c event or rather represents a
general phenomenon. Therefore, we tested the possibility of
inducing a protective immune response to autologous Pmel17/
gp100 in a melanoma model on an H-2d background. We found
that genetic vaccination with autologous Pmel17/gp100 plasmid
DNA (pDNA) can protect DBA/2 mice against a challenge with
Cloudman S91 clone M3 melanoma cells as a result of a Pmel17/
gp100-speci®c T cell response. These results indicate that effective
antimelanoma immunity can be induced in vivo even against
autoantigens and make Pmel17/gp100 a candidate molecule for the
preclinical as well as clinical evaluation of antigen-speci®c
vaccination strategies against melanoma.
MATERIALS AND METHODS
Mice Female 6±10-wk-old DBA/2 (H-2d) mice were purchased from
Charles River Wiga GmbH (Sulzfeld, Germany) and held under speci®c-
pathogen-reduced conditions in the Central Animal Laboratory, University
of Essen (Essen, Germany). All animal experiments were approved by the
regulatory committee on animal welfare in the state of Northrhine-
Westfalia.
Cell lines Clone M3 (derived from Cloudman S91 melanoma; H-2d)
(Yasumura et al, 1966), P815 mouse mastocytoma (H-2d), and Yac-1 cells
were obtained from the American Type Culture Collection (ATCC),
Rockville, MD. M3 melanoma cells were cultured in Ham's F10 medium
(Life Technologies, Grand Island, NY) supplemented with 2.5% heat-
inactivated fetal bovine serum (Gibco BRL, Eggenstein, Germany), 12.5%
horse serum (Life Technologies), 0.1 mM nonessential amino acids (Gibco
BRL), 25 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, and
5 3 10±5 M 2-mercaptoethanol (Life Technologies) in gelatin-coated
culture ¯asks (Becton Dickinson, Heidelberg, Germany). Immunocyto-
chemical analysis of M3 cells revealed a heterogeneous Pmel17/gp100
expression pattern with approximately 50% of the cells being positive. We
used limiting dilution and selection for Pmel17/gp100-positive and
Pmel17/gp100-negative M3 cells to establish lines uniformly expressing
Pmel17/gp100 (e.g., M3-7 Pmel17 high-expressing line; more than 95% of
the cells are positive for Pmel17 as detected by means of immuno-
cytochemistry with antibody HMB45 (Dako, Hamburg, Germany)) or
being negative for the antigen of interest (e.g., M3-1; less than 5% of the
cells react with antibody HMB45). The Pmel17/gp100 status of these cells
was regularly checked by ¯uorescence-activated cell sorter (FACS) analysis
or immunostaining of cytospin preparations (Fig 1). All other cell lines
(P815, YAC-1) were cultured in RPMI 1640 (Life Technologies)
supplemented with 10% fetal bovine serum, HEPES, nonessential amino
acids, L-glutamine, sodium pyruvate, and 2-mercaptoethanol as described
above. All cells were cultured at 37°C in a humidi®ed 5% CO2
atmosphere.
Genetic vaccination and tumor challenge The murine Pmel17
pDNA (VR1012/mPmel17) construct under the control of the human
CMV intermediate-early promotor was generated by ligation of the murine
H2d-derived full length Pmel17 cDNA sequence (Weimann et al, 2000)
into the NotI cloning site of the eukaryotic plasmid expression vector
VR1012 (kindly provided by B. Zaugg, Vical, San Diego, CA). Correct
orientation and murine Pmel17 sequence were con®rmed by automated
sequencing on an ABI PRISM genetic analyzer (PE Biosystems,
Weiterstadt, Germany). pDNA was af®nity-puri®ed with the Endo-free
Plasmid Mega Kit (Quiagen, Hilden, Germany) and all pDNA contained
less than 0.04 IU per mg of endotoxin, as determined by the Limulus
amoebocyte lysate analysis kit (QCL-1000, BioWhittaker, Walkersville,
MD).
DBA/2 mice were injected intradermally into one side of the back with
50 mg of VR1012/mPmel17 twice in a 2 wk interval. Control animals
received 50 mg control vector pDNA alone. Two weeks later, animals were
challenged by the subcutaneous implantation of 5 3 105 Pmel17high M3-7
or Pmel17low M3-1 cells into the back contralaterally to the immunization
site. Tumor growth was monitored every 2±3 d. All in vivo experiments
were read in a blinded, randomized fashion. In an additional set of
experiments, Pmel17/gp100-immunized animals that had rejected an M3
melanoma challenge were rechallenged subcutaneously with 1 3 105
syngeneic P815 mastocytoma cells at week 8 after original implantation
of M3 tumor cells.
In vivo T cell depletion To deplete T cells in vivo, animals received
intraperitoneal injections of anti-CD4 (0.3 mg GK1.5) and anti-CD8
(0.3 mg YTS169) antibody solutions at days 11, 12, and 13 after the second
immunization. This treatment led to a reduction by more than 95% of
splenic CD3-positive cells as determined by FACS analysis (not shown).
On day 14 after the second vaccination, mice were subcutaneously
inoculated with M3-7 melanoma cells and monitored for the appearance
and growth of tumors as described.
Cytotoxicity assay Spleens were removed 2 wk after the second
vaccination from mice genetically immunized with murine Pmel17/
gp100 pDNA and from control mice (naive). A total of 4 3 106 splenocytes
per well were restimulated for 5 d in 24 well tissue culture plates (Becton
Dickinson, Heidelberg, Germany) with 1 3 105 M3-7 cells that had been
interferon-g treated (200 U per ml for 18 h; Genzyme, Framingham, MA)
and subsequently paraformaldehyde ®xed (0.5% paraformaldehyde for
10 min at 37°C) as described previously (Zatloukal et al, 1995).
Recombinant human interleukin-2 (Cetus, Emeryville, CA) was added
at a ®nal concentration of 10 U per ml. Lysis of target cells mediated by
restimulated splenocytes was determined in a 4 h standard 51Cr-release
assay. For this purpose, 5 3 103 target cells labeled with Na2[51Cr]O4 (ICN,
Eschwege, Germany) were coincubated with splenocytes at various
effector-to-target ratios in triplicate U-bottomed 96 well plates (Greiner,
Solingen, Germany) in a ®nal volume of 200 ml. 51Cr released into the
supernatant of microtiter wells was quanti®ed in a liquid scintillation
counter (Beckman LS-6000, Munich, Germany). Target cells included
M3-7 and M3-1 melanoma cells and Yac-1 cells as natural killer cell lysis
control. When used as target cells in 51Cr-release assays, Pmel17high M3-7
and Pmel17low M3-1 melanoma cells were prestimulated with 200 U per ml
interferon-g for 18 h as described above. To generate lymphokine-activated
Figure 1. MAA Pmel17/gp100 expression in melanoma subclones
derived by limiting dilution from Cloudman S91 melanoma cell
line M3 (H-2d). Analysis of intracellular antigen expression by ¯ow
cytometric as well as immunocytochemical analysis with monoclonal
antibody HMB45 reveals high expression levels of MAA Pmel17/gp100 in
subline M3-7, consequently designated as Pmel17high-expressing M3-7
subline (A). In contrast, subline M3-1 reveals only low intracellular
expression levels of MAA Pmel17/gp100 and was therefore designated as
Pmel17low-expressing M3-1 subline (B).
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killer cells, splenocytes of naive animals were cultured for 5 d in complete
medium supplemented with recombinant human interleukin-2 (200 U
per ml, Cetus). The percentage of speci®c lysis was calculated as [(sample
cpm ± spontaneous cpm)/(maximal cpm ± spontaneous cpm)] 3 100. In all
experiments spontaneous release was between 10% and 20% of the
maximum release obtained by treatment with 1% Triton X-100 (Sigma,
Deisenhofen, Germany).
Immunohistochemistry Analysis of Pmel17 expression of cultured cell
lines and excised tissue specimens was performed by use of the Pmel17/
gp100-reactive monoclonal antibody HMB45 (Wagner et al, 1995).
Cytospin preparations of cell lines were ®xed in methanol/acetone for
90 s at room temperature, incubated with monoclonal antibody HMB45
diluted 1:100 for 1 h at room temperature, and, for visualization of the
immune reaction, subjected to APAAP staining essentially as described by
Wagner et al (1995). Excised tissue blocks were ®xed immediately in
buffered formaldehyde at pH 7.0 and embedded in paraf®n wax, and
immunostaining of 2 mm tissue sections was performed as described above.
Negative controls included omission of the ®rst, second, and/or third
antibody layer and substitution of the primary antibody by rabbit
preimmune or nonimmune IgG. Melanoma lesions were scored
according to S. Ferrone (Valhalla, NY) as follows: positive when the
percentage of immunostained melanoma cells in the entire lesion exceeded
75%, heterogeneous when the percentage ranged between 75% and 25%,
and negative when the percentage was less than 25%.
Statistical analysis The Fisher's exact test was used to evaluate statistical
differences in tumor protection rates between genetically and control
vaccinated mice.
RESULTS
Intradermal injection of autologous Pmel17/gp100 pDNA
protects mice against the growth of Pmel17/gp100-
expressing melanoma cells Cloudman S91 clone M3 cells
(hereafter referred to as M3) constitutively express low levels of
major histocompatibility complex (MHC) class I (H-2d), CD44,
and CD54, but lack MHC class II and B7-1/2 molecules (Zatloukal
et al, 1995). Incubation with interferon-g upregulates MHC class I
and CD54 molecules slightly but fails to induce MHC class II and
B7-1/2 molecules on these cells (data not shown). To titrate the
number of cells capable of establishing tumors in vivo, syngeneic
DBA/2 mice were challenged with increasing numbers of
Pmel17high M3-7 and Pmel17low M3-1 melanoma cells. In
accordance with the results of Zatloukal et al obtained with
parental M3 cells (Zatloukal et al, 1995), melanomas developed at
the injection sites after subcutaneous inoculation of 1 3 103
Pmel17high M3-7 as well as Pmel17low M3-1 cells in 50% of the
animals and after inoculation of 3 3 103 tumor cells in 100% of the
animals. After subcutaneous application of 1 3 105 of Pmel17high
M3-7 as well as 1 3 105 Pmel17low M3-1 cells, melanomas appeared
within 15 d in 100% of the animals with similar kinetics (Fig 2).
Therefore, the dose of 1 3 105 cells was chosen for further
experiments. At autopsy, tumor in®ltration of tissues surrounding
the injection site could be observed, but no formation of
macroscopically detectable visceral metastases.
To study the induction of an antigen-speci®c immune response
by application of a pDNA vaccine, mice received two injections of
the VR1012/mPmel17 pDNA encoding the autologous melano-
ma-associated antigen Pmel17/gp100 or of the control pDNA
VR1012 and were then challenged with Pmel17high M3-7 cells. In
pooled results from two sets of experiments (®ve and ten animals,
respectively), more than half of the animals that had received
VR1012/mPmel17 pDNA were protected completely (eight of
15 = 53.3%) against the highly tumorigenic dose of 1 3 105 M3-7
cells. None of these protected animals developed a tumor at a later
time point during an entire observation period of 4 mo (Fig 3A).
By contrast, control animals that had been injected with vector
VR1012 pDNA alone consistently failed to reject Pmel17high M3-7
melanoma cells (Fig 3A, p < 0.0009). To study whether T cells are
involved in the processes that lead to the elimination of the M3-7
cells, animals that had received two injections of VR1012/
mPmel17 pDNA or control VR1012 pDNA were depleted of T
lymphocytes before being challenged with M3-7 melanoma cells.
Figure 4 shows that depletion of CD4- and CD8-positive T
lymphocytes in VR1012/mPmel17 pDNA-injected mice com-
pletely abrogates the protective effect that this vaccine exerts. These
results indicate that direct injection of pDNA encoding autologous
TAA Pmel17/gp100 can generate a protective, T-cell-mediated
immune response against Pmel17/gp100-expressing melanoma
cells. Autoimmune phenomena such as depigmentation of the hair
coat reported for genetic vaccination with the murine or human
melanoma differentiation antigen TRP-1 in C57BL/6 J mice
(Weber et al, 1998; Overwijk et al, 1999) were not observed.
Intradermal application of autologous Pmel17/gp100 pDNA
activates antigen-speci®c Tcells DNA immunization strategies
have been shown to induce antigen-speci®c humoral as well as
Figure 2. Tumor development after subcutaneous inoculation of
1 3 105 Pmel17high-expressing M3-7 and Pmel17low-expressing M3-1
melanoma cells into naive syngeneic DBA/2 mice. Note that the
tumors emerge and grow with similar kinetics.
Figure 3. Administration of pDNA coding for Pmel17/gp100
protects animals against the growth of melanomas in an antigen-
speci®c manner. More than 50% of DBA/2 mice immunized with
VR1012/mPmel17 pDNA are protected against a subsequent challenge
with Pmel17high-expressing M3-7 melanoma cells whereas animals that
received the control pDNA VR1012 failed to reject the inoculated
melanoma cells (p < 0.0009) (A). In contrast, for tumor challenge with
Pmel17low-expressing M3-1 melanoma cells, VR1012/mPmel17 pDNA-
immunized mice do not reject tumor cells at levels over background as
obtained by control pDNA VR1012-injected mice (p = 0.73) (B).
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cellular immune responses in vivo (Irvine et al, 1996; Schreurs et al,
1998). To gain insight into the mechanism of pDNA-induced
immunity, we asked whether an antigen-speci®c CTL response can
be elicited by genetic immunization with VR1012/mPmel17
pDNA. To this end, splenocytes from immunized or naive mice
were stimulated by coculture with paraformaldehyde-®xed
Pmel17high M3-7 melanoma cells and were then tested for the
presence of antigen-speci®c CTL. Results obtained showed that
splenocytes from Pmel17/gp100 pDNA-injected animals lyzed
Pmel17high M3-7 but not Pmel17low M3-1 melanoma cells
(Fig 5A). By contrast, splenocytes from naive mice failed to induce
signi®cant lysis of M3-7 targets (Fig 5B). The lysis of the M3-7 cells
by splenocytes of pDNA-injected animals was apparently not
mediated by natural killer cells as these splenocytes did not lyze the
natural killer cell target YAC-1 (Fig 5C). Together with the
observation of a comparable sensitivity of Pmel17high M3-7 and
Pmel17low M3-1 melanoma cells to lysis by lymphokine-activated
killer cells or H-2d-speci®c allogeneic CTL, respectively (not shown),
these results indicate that the intradermal injection of autologous
Pmel17/gp100 pDNA induces a Pmel17/gp100-speci®c CTL
response.
MAA Pmel17/gp100 represents the target of the protective T
cell immune response induced by genetic vaccination We
attempted to determine why only 50% of the Pmel17/gp100 pDNA-
injected animals were protected because this may contribute to our
understanding of relevant mechanisms underlying successful immune
responses. Therefore, we compared in vivo progressing variants of
Pmel17high M3-7 melanoma cells in VR1012/mPmel17 pDNA-
immunized mice with those arising in control VR1012 pDNA-
immunized mice for their Pmel17/gp100 MAA expression. As
shown in Fig 6(A, B), positive immunostaining of tumors for MAA
Pmel17/gp100 was readily observed in almost all tumors (eight of
nine tumors analyzed) developing in control vaccinated mice,
whereas all tumors developing in VR1012/mPmel17 pDNA-
injected animals failed to exhibit HMB45 reactivity (eight of eight
tumors analyzed). These results suggest that downregulation or
absenceofPmel17/gp100expression aremechanismsbywhichM3-7
cells escape immunologic control induced by intradermal injection of
VR1012/mPmel17 pDNA.
To further delineate the role of MAA Pmel17/gp100 expression
in tumor rejection Pmel17low-expressing M3-1 melanoma cells
were applied to mice immunized with VR1012/mPmel17 pDNA.
As can be seen in Fig 3(B), tumor development in these animals
was comparable with that in control mice vaccinated with vector
VR1012 pDNA alone, indicating no signi®cant protective effect
Figure 4. Tumor development of Pmel17high M3-7 melanoma cells
in VR1012/mPmel17 pDNA-immunized mice in vivo depleted of
CD4+ and CD8+ T cells as described in the Material and Methods
section. Note the complete loss of tumor protection induced by antigen-
speci®c immunization with pDNA.
Figure 5. Intracutaneous genetic vaccination with VR1012/
mPmel17 pDNA results in the generation of an antigen-speci®c
CTL response. Splenocytes from mice immunized with VR1012/
mPmel17 pDNA and stimulated as described in the Materials and Methods
section lyze Pmel17high-expressing M3-7 melanoma cells but not the
histogenetically identical Pmel17low-expressing M3-1 melanoma cells (A).
No lysis of either M3-7 or M3-1 is seen when spleen cells of naive mice
were used as effector cells (B). Natural killer cell target YAC-1 cells are not
lyzed by splenocytes from either mice immunized with VR1012/m
Pmel17 pDNA or naõÈve mice (C).
Figure 6. Immunohistochemical analysis of the antigen expression
pattern of M3-7 tumors in Pmel17/gp100-experienced or Pmel17/
gp100-naive hosts: evidence for immune escape through antigen
loss. Melanomas developing in control VR1012 pDNA immunized mice
express Pmel17/gp100 as revealed by staining with monoclonal antibody
HMB45 (a). By contrast, tumors growing upon inoculation of Pmel17high-
expressing M3-7 melanoma cells into mice genetically immunized with
VR1012/mPmel17 pDNA have lost their Pmel17/gp100 expression (b).
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induced by vaccination with VR1012/mPmel17 pDNA against
Pmel17low-expressing melanoma cells (p = 0.73). We further
observed that injection of histogenetically unrelated Pmel17negative
P815 mastocytoma cells resulted in tumor development in
VR1012/mPmel17 pDNA-immunized mice, even in those that
had rejected an M3-7 melanoma inoculum previously (Fig 7).
Again, tumor growth in these animals was comparable with that
seen in control vaccinated mice (Fig 7). Taken together, these
results indicate that, in contrast to Pmel17/gp100-expressing M3-7
cells, tumor cells lacking or having lost Pmel17/gp100 grow
progressively in mice genetically immunized with autologous
Pmel17/gp100 pDNA, thereby demonstrating that MAA Pmel17/
gp100 represents a true tumor rejection antigen in the M3-DBA/2
experimental melanoma model.
DISCUSSION
In this study, we have demonstrated (i) that mice that had received
intradermal injections of pDNA coding for Pmel17/gp100 show
signi®cant protection against subsequent challenge with melanoma
cells expressing the respective tumor-associated antigen but not
against challenge with antigen-negative histogenetically identical or
unrelated tumor cells; (ii) that this protective effect is mediated by
T cells in vivo; (iii) that a corresponding Pmel17/gp100-speci®c T
cell response can be detected in immunized mice; and (iv) that
tumor escape variants in immunized mice consistently demon-
strated absence of MAA Pmel17/gp100 expression. Taken
together, these results indicate that intradermal application of a
pDNA encoding autologous MAA Pmel17/gp100 can lead to
protection against an otherwise lethal dose of melanoma cells as a
result of the induction of an antigen-speci®c and protective T-cell-
mediated immune response.
So far, the protective effects induced by Pmel17/gp100-based
genetic vaccines have been evaluated exclusively in the B16-
C57BL/6 mouse melanoma model. Studies assessing variables such
as the form of the antigen (autologous versus xenogeneic), various
vector constructs, as well as routes of vaccine application revealed
that protective immune responses can be elicited exclusively or
predominantly with the xenogeneic human form of Pmel17/gp100
(Zhai et al, 1996; MoÈlling et al, 1997; Schreurs et al, 1998; Kaplan
et al, 1999). It has been argued that the reason for this is the
presence of a peptide homolog within the human Pmel17/gp100
with high avidity to H-2b class I molecules able to initiate a
crossreactive T cell response towards its murine counterpart
(Overwijk et al, 1998). Similar results were obtained with TRP-1
and TRP-2. When administered by gene gun or with adenovirus,
only constructs containing the DNA sequence of the human TRP-
1 and TRP-2 induced protective immunity in the B16 melanoma
model (Weber et al, 1998; Steitz et al, 2000). These results led to the
assumption that DNA-based immunization strategies are not
powerful enough to break the state of nonresponsiveness to
autologous melanocyte differentiation antigens and thus to generate
protective immunity against melanoma. Most recently, however,
Overwijk et al and Bronte et al demonstrated that the induction of
antigen-speci®c cellular immunity against melanocyte differenti-
ation antigens in the B16-C57BL/6 model can be accomplished
either by using a recombinant vaccinia vector encoding the
autologous form of TRP-1 or by intramuscular inoculation of
pDNA encoding TRP-2 (Overwijk et al, 1999; Bronte et al, 2000).
Reasons why the use of a certain vehicle or a certain site of
application may be superior for inducing protective cancer
immunity include differences in gene expression levels obtained,
in the immunologic compartments reached, and in the in¯amma-
tory changes (resulting in the activation of antigen-presenting cells)
induced by the respective vehicles. Obviously, these factors may
become critical when the immunogenicity of a given antigen is
limited as is the case with autoantigens.
Concerning the capacity to induce a productive immune
response against autologous melanocyte differentiation antigens,
adoptive transfer of dendritic cells appears to exceed the effects
obtained with recombinant vaccinia virus. This notion is based on
the observation that injection of dendritic cells genetically
engineered to express autologous TRP-2 protected C57BL/6
mice against the growth of B16 melanoma (Kaplan et al, 1999)
whereas this could not be achieved with a recombinant vaccinia
virus encoding this antigen (Overwijk et al, 1999). This view is
further supported by the ®nding that dendritic cells transduced with
an adenovirus encoding the autologous form of Pmel17/gp100 can
protect a subset of vaccinated animals against a challenge with B16
melanoma cells (Kaplan et al, 1999). Following this reasoning, our
success in inducing a protective antimelanoma immune response to
autologous Pmel17/gp100 may re¯ect the capacity of our vector to
yield high gene expression in host antigen-presenting cells (Casares
et al, 1997; Torres et al, 1997; Chattergoon et al, 1998).
Alternatively, the immunologic ef®cacy of this vector may result
from its CpG sequences as such motifs have been shown to enhance
the immunostimulatory potency of dendritic cells and to polarize
immune responses towards a Th1 phenotype (Tighe et al, 1998).
Another difference to previous studies that failed to induce an
immune response to autologous Pmel17/gp100 using pDNA-based
vaccines is the genetic background of the mouse strain employed.
Whereas previous studies were predominantly done in C57BL/6
mice (H-2b), we used DBA/2 mice that express H-2d MHC
molecules. As various MHC moieties bind different arrays of
antigenic peptide epitopes, this selection may account for the
differences obtained. Furthermore, it is conceivable that, in
different mouse strains, different mechanisms are responsible for
the state of nonresponsiveness towards self-antigens such as
Pmel17/gp100. These may include central and peripheral toler-
ance, antigen ignorance, and regulatory T lymphocytes. According
to the pathway(s) involved, the requirements to overcome its/their
functional consequence(s) will differ substantially. Obviously, a
more detailed understanding of these mechanisms will help to
improve the ef®cacy of self-antigen-based vaccination strategies.
To our surprise, we did not observe phenomena indicative of
melanocyte destruction (e.g., depigmentation of the hair coat),
which are reported to accompany ef®cient genetic vaccinations
with the autologous or xenogeneic human melanoma differenti-
ation antigens TRP-1 and TRP-2 in C57BL/6 J mice (Weber et al,
1998; Overwijk et al, 1999; Steitz et al, 2000). When, for the
purpose of inducing antitumor immunity, tolerance towards self-
antigens is broken, antitumor immune responses are usually
accompanied by autoimmune phenomena (Weber et al, 1998;
Overwijk et al, 1999; Pardoll, 1999; Steitz et al, 2000). We now
know, however, that this must not necessarily be the case. For
example, neither Schreurs et al, Kaplan et al nor, most recently,
Bronte et al reported the occurrence of such events despite
inducing potent immune responses against the melanocytic self-
antigens Pmel17/gp100 or TRP-2 (Schreurs et al, 1998; Kaplan
et al, 1999; Bronte et al, 2000). As antitumor immune responses are
Figure 7. Growth characteristics of syngeneic Pmel17negative P815
mastocytoma cells after injection of 1 3 105 viable cells into
VR1012/mPmel17 pDNA-immunized mice that had successfully
rejected a challenge with Pmel17high M3-7 melanoma cells. Note
that VR1012/mPmel17 pDNA-immunized mice that had rejected a
challenge with M3-7 cells develop tumors upon injection of P815 cells.
These tumors grow at a rate comparable with that observed in control mice
injected with VR1012 pDNA alone.
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critically dependent on the expression level of antigens, this
apparent dissociation could be due to the signi®cantly different
expression levels of Pmel17/gp100 between melanocytes and
melanoma cells. Such differences have been reported previously in
humans (Wagner et al, 1997) and may also be present in the mouse
system with DBA/2 mice exhibiting only intermediate pigment-
ation of the hair coat. According to the energy diagram of tumor
immunity recently proposed by Pardoll (1999) our results indicate
that the appearance of autoimmune phenomena simultaneously
with antitumor immunity on one hand and the complete lack of
antitumor immunity on the other side may represent opposite
extremes of the immune response. Between these, intermediate
situations may exist where antitumor immunity can be elicited
without the development of autoimmune phenomena. The fact
that vaccination with autologous melanocyte differentiation
antigens can result in protective antimelanoma immunity in the
absence of autoimmunity has important implications for the
development of pDNA melanoma vaccines for man because, thus
far, differentiation antigens are the only type of antigen shown to
function as tumor rejection antigens ± both in animal models
(Irvine et al, 1996; Kaplan et al, 1999; Overwijk et al, 1999; this
study) and in a clinical setting (Kawakami et al, 1995). Whereas the
overall clinical bene®t of genetic vaccines for melanoma patients is
still unclear, the data presented in our study may encourage clinical
trials employing antigen-based genetic vaccination strategies at least
in an adjuvant setting. In view of its homogenous expression (at
levels signi®cantly higher than in melanocytes) in primary tumors
and metastatic lesions and its expression by the tumors of nearly all
melanoma patients (Wagner et al, 1997), MAA Pmel17/gp100 may
represent a promising candidate antigen for those strategies.
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